Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252
Authors:
- Johann BauersachsJBJohann Bauersachs
- Claude BraunCBClaude Braun
- Daniela FraccarolloDFDaniela Fraccarollo
- Julian WidderaJWJulian Widdera
- Georg ErtlGEGeorg Ertl
- Lothar SchillingLSLothar Schilling
- Michael KirchengastMKMichael Kirchengast
- Peter RohmeissPRPeter Rohmeiss
- 1 October 2000
- journal article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 18 (10) , 1507-1514
Abstract
To investigate the role of an activated endothelin system in the renal dysfunction observed in chronic heart failure after myocardial infarction. In rats with heart failure after myocardial infarction and in sham-operated animals (Sham), we investigated the effect on renal function of long-term oral treatment with the selective endothelin A (ETA) receptor antagonist, LU 135252 (30 mg/kg per day; groups MI/LU and Sham/LU) or placebo (groups MI/P, Sham/P). Only animals with extensive myocardial infarction (at least 46% of the left ventricle) were included in the study. Infarct size was matched between groups MI/P and MI/LU. Endogenous creatinine clearance, fractional sodium excretion, and plasma and urinary concentrations of endothelin were determined 12 weeks after myocardial infarction. Endogenous creatinine clearance was significantly lower in group MI/P than in group Sham/P (MI/P: 0.64 +/- 0.05, Sham/P: 0.81 +/- 0.04 ml/min per 100 g body weight; P= 0.01 (means +/- SEM)). Treatment with LU 135252 completely prevented the decline in creatinine clearance in rats with chronic myocardial infarction (MI/LU: 0.98 +/- 0.21; Sham/LU: 0.83 +/- 0.10). Fractional sodium and protein excretion did not differ among the four groups. Group MI/P had a marked increase in plasma endothelin concentrations, which was not affected by treatment with LU 135252. Urinary endothelin excretion was significantly lower in group MI/P than in group Sham/P. In the treatment groups, no difference could be observed between animals that had suffered myocardial infarction and the sham-operated group, although LU 135252 markedly increased the urinary excretion of endothelin. Our data demonstrate a restoration of impaired renal function in chronic ischaemic heart failure by treatment with the selective ETA receptor antagonist, LU 135252. These results offer a promising therapeutic option for the treatment of renal insufficiency in patients with chronic heart failure.Keywords
This publication has 31 references indexed in Scilit:
- PREVENTION OF CHRONIC RENAL ALLOGRAFT REJECTION IN RATS WITH AN ORAL ENDOTHELIN A RECEPTOR ANTAGONIST1Transplantation, 1999
- Pharmacology of the EndothelinAReceptor Antagonist: LU 135252Cardiovascular Drug Reviews, 1998
- Endothelin in hypertension: A role for receptor antagonists?Cardiovascular Research, 1998
- Nephroprotection of an ETA-Receptor Blocker (LU 135252) in Salt-Loaded Uninephrectomized Stroke-Prone Spontaneously Hypertensive RatsHypertension, 1998
- Endothelin Antagonism in End-Organ Damage of Spontaneously Hypertensive RatsHypertension, 1996
- An endothelin-1 mediated autocrine growth loop involved in human renal tubular regenerationKidney International, 1995
- Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivityKidney International, 1994
- Renal endothelin gene expression is increased in remnant kidney and correlates with disease progressionKidney International, 1993
- Alterations in renal endothelin-1 production in the spontaneously hypertensive rat.Hypertension, 1992
- Calcitonin gene-related peptide-like immunoreactivities in pheochromocytomasPeptides, 1989